Butchertown Clinical Trials and The Eye Care Institute Announce Our 13th FDA Approval Dextenza®

October 18, 2021

For Immediate Release

Ocular Therapeutix, a Bedford, MA company, has announced the FDA has approved Dextenza® for treating ocular itching associated with allergic conjunctivitis.

John C. Meyer, MD, of The Eye Care Institute and Butchertown Clinical Trials, was a principal investigator for the clinical trials leading to the FDA approval of this new treatment option for persons suffering from itchy eyes due to seasonal allergies. Dr. Meyer stated, “dissolvable implants are inserted into the puncta in an eye doctor’s office. The implants contain a preservative-free topical steroid medication which is time-released over 30 days.” Dr. Meyer continued, “the implants are painless and effective for treating allergic eye conditions, with the biggest advantage being that patients should not need eye drops to relieve symptoms of allergic conjunctivitis. It’s a hands-free way to be more comfortable during allergy season.”

Michael Goldstein, MD, President and Chief Medical Officer of Ocular Therapeutix, stated, “DEXTENZA can now provide an office-based, physician-administered, preservative-free method of steroid delivery that benefits patients with ocular itching associated with allergic conjunctivitis.” This is the 13th FDA-approved drug or device for Louisville, KY-based Butchertown Clinical Trials. Many people who live in the area suffer from seasonal allergies due to the Ohio River Valley, and this trial is one more way Butchertown Clinical Trials helps improve human health. Depending on production and availability, these implants will soon be available in eye doctors’ offices for allergy sufferers.

#          #          #